Athira Pharma, Inc. (ATHA) Stock Analysis & Investment Frameworks

Athira Pharma, Inc. (ATHA) stock analysis on Invetso. Review Athira Pharma, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Athira Pharma, Inc. Company Overview

Athira Pharma, Inc. Key Financial Metrics

About Athira Pharma, Inc.

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.

Athira Pharma, Inc. Investment Frameworks

Invetso analyzes Athira Pharma, Inc. (ATHA) across the following frameworks:

Explore More ATHA Research